Scanning a DRB3*0101 (DR52a)-Restricted Epitope Cross-Presented by DR3: Overlapping Natural and Artificial Determinants in the Human Acetylcholine Receptor
Author:
Nagvekar Nita1, Corlett Louise1, Jacobson Leslie W.1, Matsuo Hidenori1, Chalkley Robert2, Driscoll Paul C.2, Deshpande Shrikant3, Spack Edward G.3, Willcox Nicholas1
Affiliation:
1. *Neuroscience Group, Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom; 2. †Ludwig Institute for Cancer Research, and Department of Biochemistry and Molecular Biology, University College, London, United Kingdom; and 3. ‡Anergen Inc., Redwood City, CA 94063.
Abstract
AbstractA recurring epitope in the human acetylcholine receptor (AChR) α subunit (α146–160) is presented to specific T cells from myasthenia gravis patients by HLA-DRB3*0101—“DR52a”—or by DR4. Here we first map residues critical for DR52a in this epitope by serial Ala substitution. For two somewhat similar T cells, this confirms the recently deduced importance of hydrophobic “anchor” residues at peptide p1 and p9; also of Asp at p4, which complements this allele’s distinctive Arg74 in DRβ. Surprisingly, despite the 9 sequence differences in DRβ between DR52a and DR3, merely reducing the bulk of the peptide’s p1 anchor residue (Trp149→Phe) allowed maximal cross-presentation to both T cells by DR3 (which has Val86 instead of Gly). The shared K71G73R74N77 motif in the α helices of DR52a and DR3 thus outweighs the five differences in the floor of the peptide-binding groove. A second issue is that T cells selected in vitro with synthetic AChR peptides rarely respond to longer Ag preparations, whereas those raised with recombinant subunits consistently recognize epitopes processed naturally even from whole AChR. Here we compared one T cell of each kind, which both respond to many overlapping α140–160 region peptides (in proliferation assays). Even though both use Vβ2 to recognize peptides bound to the same HLA-DR52a in the same register, the peptide-selected line nevertheless proved to depend on a recurring synthetic artifact—a widely underestimated problem. Unlike these contaminant-responsive T cells, those that are truly specific for natural AChR epitopes appear less heterogeneous and therefore more suitable targets for selective immunotherapy.
Publisher
The American Association of Immunologists
Subject
Immunology,Immunology and Allergy
Reference46 articles.
1. Marsh, S. G., J. E. Moses, J. G. Bodmer. 1992. HLA class II sequence polymorphism detectable by serology. K. Tsuji, and M. Aizawa, and T. Sasazuki, eds. HLA 1991 610 Oxford University Press, Oxford, U.K. 2. Krieger, J. I., R. W. Karr, H. M. Grey, W. Y. Yu, D. O’Sullivan, L. Batovsky, Z. L. Zheng, S. M. Colon, F. C. A. Gaeta, J. Sidney, et al 1991. Single amino acid changes in DR and antigen define residues critical for peptide-MHC binding and T cell recognition. J. Immunol. 148: 2331 3. Demotz, S., C. Barbey, G. Corradin, A. Amoroso, A. Lanzavecchia. 1993. The set of naturally processed peptides displayed by DR molecules is tuned by polymorphism of residue 86. Eur. J. Immunol. 23: 425 4. Newton-Nash, D. K., D. D. Eckels. 1993. Differential effect of polymorphism at HLA-DR1 β-chain positions 85 and 86 on binding and recognition of DR1-restricted antigenic peptides. J. Immunol. 150: 1813 5. O’Sullivan, D., J. Sidney, E. Appella, L. Walker, L. Phillips, S. M. Colon, C. Miles, R. W. Chesnut, A. Sette. 1990. Characterization of the specificity of peptide binding to four DR haplotypes. J. Immunol. 145: 1799
|
|